Form 4: Jazz Pharmaceuticals EVP Philip L. Johnson Reports Acquisition of Shares

Philip L. Johnson, EVP & Chief Financial Officer of Jazz Pharmaceuticals, reports the acquisition of ordinary shares, including restricted stock units, in a recent SEC Form 4 filing.

Summary

• Philip L. Johnson, the EVP & Chief Financial Officer of Jazz Pharmaceuticals, filed a Form 4 with the SEC.
• The filing reports the acquisition of 12,000 ordinary shares at a price of $119.65 on March 1, 2024.
• Johnson also acquired 15,932 restricted stock units on March 1, 2024, granted under the company's 2011 Equity Incentive Plan.
• These restricted stock units vest in equal annual installments over four years, starting March 5, 2024.
• Following these transactions, Johnson beneficially owns 27,932 ordinary shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing detailing stock transactions by an executive. The acquisition of shares could be seen as a slightly positive signal, but it's primarily an informational document.

Positives

• The acquisition of shares by a high-ranking executive could be interpreted as a positive signal regarding their confidence in the company's future prospects.

Future Outlook

The restricted stock units will vest in equal annual installments over four years, starting March 5, 2024.

Industry Context

Executive stock acquisitions are common in the pharmaceutical industry as part of compensation packages and can reflect management's alignment with shareholder interests.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include stock options and restricted stock units to incentivize performance and align executive interests with those of shareholders.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize equity-based compensation as a significant component of their executive pay structures.
• The vesting schedules and terms of these equity grants are typically benchmarked against industry standards to attract and retain top talent.

Stakeholder Impact

• The acquisition of shares by an executive may have a minor positive impact on shareholder sentiment.

Key Dates